Updating results

318 results for template

Sort: Relevance | Date

Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

Technology appraisal guidance Published August 2006 Last updated November 2013

Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published July 2009

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus

Technology appraisal guidance Published July 2008

Chronic heart failure in adults (QS9)

This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

Quality standard Published June 2011 Last updated September 2018

Antenatal and postnatal mental health (QS115)

This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.

Quality standard Published February 2016

Stroke in adults (QS2)

This quality standard covers diagnosing and managing stroke in adults (over 16). It includes diagnosis, initial management, acute-phase care, rehabilitation and long-term support for people with stroke. It describes high-quality care in priority areas for improvement.

Quality standard Published June 2010 Last updated April 2016

Obesity: clinical assessment and management (QS127)

This quality standard covers assessing and managing obesity in adults, young people and children, including referral for specialist care and bariatric (weight loss) surgery. It includes people who are obese and have, or are at risk of, other medical conditions. It describes high-quality care in priority areas for improvement.

Quality standard Published August 2016

Chronic obstructive pulmonary disease in adults (QS10)

This quality standard covers assessing, diagnosing and managing chronic obstructive pulmonary disease (COPD). It describes high-quality care in priority areas for improvement.

Quality standard Published July 2011 Last updated February 2016

Resource impact reports and templates

Disclaimer These resources are implementation tools and should be used alongside the published guidance. The information does not supersede or replace

Published June 2016 Last updated June 2016

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma

Technology appraisal guidance Published March 2009

Social care for older people with multiple long-term conditions (QS132)

This quality standard covers the planning and delivery of social care and support for older people (aged 65 and over) with multiple long-term conditions. It includes people living in their own homes, in specialist settings or in care homes, both those who receive support with funding for their social care and those who do not. It describes high-quality care in priority areas for improvement.

Quality standard Published September 2016

Alteplase for treating acute ischaemic stroke (TA264)

Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)

Technology appraisal guidance Published September 2012

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C

Technology appraisal guidance Published February 2011

Prucalopride for the treatment of chronic constipation in women (TA211)

Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women

Technology appraisal guidance Published December 2010

Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults

Technology appraisal guidance Published October 2008

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)

Evidence-based recommendations on rituximab (MabThera) for treating relapsed or refractory chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published July 2010

Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)

Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B

Technology appraisal guidance Published February 2006

Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults

Technology appraisal guidance Published July 2006

Methadone and buprenorphine for the management of opioid dependence (TA114)

Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence

Technology appraisal guidance Published January 2007

WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension (MTG13)

Evidence-based recommendations on the WatchBP Home A for opportunistically detecting atrial fibrillation (AF) when diagnosing and managing hypertension

Medical technologies guidance Published January 2013

Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)

Technology appraisal guidance Published September 2008

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

Technology appraisal guidance Published July 2012

Fellows

Fellows are experience health and social care leaders who are our ambassadors at regional and national levels

Published August 2019 Last updated August 2019

Preventing excess winter deaths and illness associated with cold homes (QS117)

This quality standard covers reducing the health risks (including preventable deaths) associated with cold homes. It includes identifying people at risk who are particularly vulnerable to the cold, such as young children, older people, and people with cardiovascular disease or mental health problems. It describes high-quality care in priority areas for improvement.

Quality standard Published March 2016

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published May 2012

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)

Technology appraisal guidance Published September 2015

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

Technology appraisal guidance Published December 2015

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)

Technology appraisal guidance Published August 2010 Last updated December 2012

The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites (MTG25)

Evidence-based recommendations on the 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites

Medical technologies guidance Published July 2015

Asthma: diagnosis, monitoring and chronic asthma management (NG80)

This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks. The investment and training required to implement the guideline will take time. In the meantime, primary care services should implement what they can of the recommendations, using currently available approaches to diagnosis until the infrastructure for objective testing is in place.

NICE guideline Published November 2017

Fever in under 5s

Everything NICE has said on assessing and initiating management of fever with no obvious cause in children under 5 in an interactive flowchart

NICE Pathway Published May 2013 Last updated October 2018

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events

Technology appraisal guidance Published December 2010

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)

Evidence-based recommendations on rituximab (MabThera) for first-line maintenance treatment of follicular non-Hodgkin's lymphoma

Technology appraisal guidance Published June 2011

Mifamurtide for the treatment of osteosarcoma (TA235)

Evidence-based recommendations on mifamurtide (Mepact) for treatment of osteosarcoma (bone cancer)

Technology appraisal guidance Published October 2011

Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating Crohn's disease in adults

Technology appraisal guidance Published May 2010

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

Evidence-based recommendations on vemurafenib (Zelboraf) for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

Technology appraisal guidance Published December 2012 Last updated January 2015

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

NICE impact: cardiovascular disease prevention

How NICE recommendations are helping to improve the prevention of cardiovascular disease

Published May 2018 Last updated May 2018

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Ticagrelor for the treatment of acute coronary syndromes (TA236)

Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes

Technology appraisal guidance Published October 2011

Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published July 2011

Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

Evidence-based recommendations on gefitinib (Iressa) for the first-line treatment of advanced or metastatic non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published July 2010

Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)

Technology appraisal guidance Published June 2007

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

Technology appraisal guidance Published February 2014

Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

Evidence-based recommendations on immunohistochemistry/microsatellite instability testing to guide tests for Lynch syndrome in people with colon cancer

Diagnostics guidance Published February 2017